Compare · LEGN vs XBIO
LEGN vs XBIO
Side-by-side comparison of Legend Biotech Corporation (LEGN) and Xenetic Biosciences Inc. (XBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LEGN and XBIO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LEGN is the larger of the two at $2.97B, about 904.1x XBIO ($3.3M).
- LEGN has been more active in the news (11 items in the past 4 weeks vs 6 for XBIO).
- LEGN has more recent analyst coverage (25 ratings vs 0 for XBIO).
- Company
- Legend Biotech Corporation
- Xenetic Biosciences Inc.
- Price
- -
- -
- Market cap
- $2.97B
- $3.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 11
- 6
- Recent ratings
- 25
- 0
Legend Biotech Corporation
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, it is developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL and targeting B-cell maturation antigen for the treatment of MM, which are currently in an investigator-initiated Phase 1 clinical trial in China. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Xenetic Biosciences Inc.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Latest LEGN
- Chief Executive Officer Ingrid Zhang bought $163,200 worth of Ordinary Shares (20,000 units at $8.16), increasing direct ownership by 2% to 1,151,860 units (SEC Form 4)
- Director Salovey Peter bought $183,250 worth of Ordinary Shares (20,000 units at $9.16), increasing direct ownership by 36% to 75,096 units (SEC Form 4)
- Legend Biotech downgraded by Evercore ISI
- SEC Form 6-K filed by Legend Biotech Corporation
- Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- Amendment: SEC Form SCHEDULE 13G/A filed by Legend Biotech Corporation
- SEC Form 6-K filed by Legend Biotech Corporation
- Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
- Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
Latest XBIO
- SEC Form DEFA14A filed by Xenetic Biosciences Inc.
- Xenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates
- SEC Form 10-Q filed by Xenetic Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Xenetic Biosciences Inc.
- Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance
- Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
- Xenetic Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Xenetic Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics